Sabiad
ActiveSabiad offers integrated diagnostic and therapeutic solutions for precise bacterial infection management.
What it does
Sabiad is a biotechnology company specializing in precision theranostics for bacterial infections, with a focus on Staphylococcus aureus. The company integrates diagnostic and therapeutic processes through its patented StaphMark platform, which employs the 1D9 antibody to accurately detect, visualize, and deliver targeted treatment for infections in real time. This technology is applicable in operating rooms and at point-of-care, addressing critical challenges in surgical infection management. By enhancing diagnostic accuracy and personalizing treatment, Sabiad aims to reduce antibiotic overuse, minimize complications, and combat antimicrobial resistance. The company’s innovative approach supports healthcare professionals in improving patient recovery and advancing healthcare efficiency.
Its site says now · captured 2026-08-26
Sabiad | Precision Theranostics for Bacterial Infections
We pioneer theranostic innovations to detect and treat bacterial infections in real time that improves patient care and healthcare efficiency.
Next to it in Healthcare and bio · Bacterial infection theranostics
- Rebio HealthPlug and Play PnP 2026
電気化学殺菌技術により、難治性のバイオフィルム感染症を低侵襲かつ高効率に解決する医療機器を開発
- Implant Preservation DevicesPlug and Play PnP 2025
Implant Preservation Devices develops a heating device for the treatment of Orthopaedic and Fracture related implant infections.
- Adipo TherapeuticsPlug and Play PnP 2026
Adipo Therapeutic is a biotechnology company that is developing a novel asset for the treatment of obesity by increasing energy expenditure via mitochondria biogenesis and activation in white adipose tissue (fat browning).
- Bahto BiosciencesPlug and Play PnP 2026
Bahto Biosciences develops non-opioid small-molecule therapeutics for painful peripheral neuropathy, a condition with limited effective treatment options that afflicts more than 19 million Americans.
- Cryton BiosciencesPlug and Play PnP 2026
Cryton Biosciences is developing a first-in-class dual-action drug that restores mitochondrial function in immune AND cancer cells resulting in tumor death.
- Diapin TherapeuticsPlug and Play PnP 2026
Novel Therapies for Cardiovascular and Metabolic Diseases
- GoldiloxBioPlug and Play PnP 2026
Transforming Drug Discovery with models that reflect human physiology.
- RNARevivePlug and Play PnP 2026
RNARevive is developing a next-generation RNA platform that enables long-lasting, low-dose protein therapeutics. Our lead candidates tackle the anti-aging and longevity space, targeting osteoporosis, age-related macular degeneration (AMD), and liver diseases.